Literature DB >> 18555826

Elevated lipid peroxidation and DNA oxidation in nerve from diabetic rats: effects of aldose reductase inhibition, insulin, and neurotrophic factors.

Joice M Cunha1, Corinne G Jolivalt, Khara M Ramos, Joshua A Gregory, Nigel A Calcutt, Andrew P Mizisin.   

Abstract

We investigated the effect of treatment with an aldose reductase inhibitor, insulin, or select neurotrophic factors on the generation of oxidative damage in peripheral nerve. Rats were either treated with streptozotocin to induce insulin-deficient diabetes or fed with a diet containing 40% d-galactose to promote hexose metabolism by aldose reductase. Initial time course studies showed that lipid peroxidation and DNA oxidation were significantly elevated in sciatic nerve after 1 week or 2 weeks of streptozotocin-induced diabetes, respectively, and that both remained elevated after 12 weeks of diabetes. The increase in nerve lipid peroxidation was completely prevented or reversed by treatment with the aldose reductase inhibitor, ICI 222155, or by insulin, but not by the neurotrophic factors, prosaptide TX14(A) or neurotrophin-3. The increase in nerve DNA oxidation was significantly prevented by insulin treatment. In contrast, up to 16 weeks of galactose feeding did not alter nerve lipid peroxidation or protein oxidation, despite evidence of ongoing nerve conduction deficits. These observations demonstrate that nerve oxidative damage develops early after the onset of insulin-deficient diabetes and that it is not induced by increased hexose metabolism by aldose reductase per se, but rather is a downstream consequence of flux through this enzyme. Furthermore, the beneficial effect of prosaptide TX14(A) and neurotrophin-3 on nerve function and structure in diabetic rats is not due to amelioration of increased lipid peroxidation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555826      PMCID: PMC2518323          DOI: 10.1016/j.metabol.2008.01.021

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  45 in total

1.  Effect of streptozotocin-induced diabetes on NGF, P75(NTR) and TrkA content of prevertebral and paravertebral rat sympathetic ganglia.

Authors:  R E Schmidt; D A Dorsey; K A Roth; C A Parvin; L Hounsom; D R Tomlinson
Journal:  Brain Res       Date:  2000-06-09       Impact factor: 3.252

Review 2.  Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.

Authors:  N E Cameron; M A Cotter
Journal:  Diabetes Res Clin Pract       Date:  1999-09       Impact factor: 5.602

3.  Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.

Authors:  I G Obrosova; C Van Huysen; L Fathallah; X Cao; M J Stevens; D A Greene
Journal:  FASEB J       Date:  2000-08       Impact factor: 5.191

Review 4.  The role of mitochondria in the pathogenesis of neurodegenerative diseases.

Authors:  G Manfredi; M F Beal
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

5.  Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction.

Authors:  S Srinivasan; M Stevens; J W Wiley
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

6.  Effects of an extracellular metal chelator on neurovascular function in diabetic rats.

Authors:  N E Cameron; M A Cotter
Journal:  Diabetologia       Date:  2001-05       Impact factor: 10.122

7.  TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in galactose-fed rats.

Authors:  A P Mizisin; R C Steinhardt; J S O'Brien; N A Calcutt
Journal:  J Neuropathol Exp Neurol       Date:  2001-10       Impact factor: 3.685

8.  Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy.

Authors:  M J Stevens; I Obrosova; X Cao; C Van Huysen; D A Greene
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

9.  An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.

Authors:  Irina G Obrosova; Carol Van Huysen; Lamia Fathallah; Xianghui Cao Cao; Douglas A Greene; Martin J Stevens
Journal:  FASEB J       Date:  2001-11-14       Impact factor: 5.191

10.  Reactions of N-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation.

Authors:  I Erdelmeier; D Gérard-Monnier; J C Yadan; J Chaudière
Journal:  Chem Res Toxicol       Date:  1998-10       Impact factor: 3.739

View more
  5 in total

Review 1.  Diabetic neuropathic pain: Physiopathology and treatment.

Authors:  Anne K Schreiber; Carina Fm Nones; Renata C Reis; Juliana G Chichorro; Joice M Cunha
Journal:  World J Diabetes       Date:  2015-04-15

2.  Neuroprotective effects of Gymnema sylvestre on streptozotocin-induced diabetic neuropathy in rats.

Authors:  Amal Jamil Fatani; Salim Salih Al-Rejaie; Hatem Mustafa Abuohashish; Abdullah Al-Assaf; Mihir Yogeshkumar Parmar; Mohammad Shamsul Ola; Mohammed Mahboobuddin Ahmed
Journal:  Exp Ther Med       Date:  2015-02-20       Impact factor: 2.447

Review 3.  Schwann cell interactions with axons and microvessels in diabetic neuropathy.

Authors:  Nádia P Gonçalves; Christian B Vægter; Henning Andersen; Leif Østergaard; Nigel A Calcutt; Troels S Jensen
Journal:  Nat Rev Neurol       Date:  2017-01-30       Impact factor: 42.937

4.  The Anti-nociceptive Effect of Ellagic Acid in Streptozotocin-induced Hyperglycemic Rats by Oxidative Stress Involvement.

Authors:  Siamak Shahidi; Alireza Komaki; Safoura Raoufi; Iraj Salehi; Mohammad Zarei; Mohamadreza Mahdian
Journal:  Basic Clin Neurosci       Date:  2021-11-01

5.  Peripheral neuropathy in rats exposed to dichloroacetate.

Authors:  Nigel A Calcutt; Veronica L Lopez; Arjel D Bautista; Leah M Mizisin; Brenda R Torres; Albert L Shroads; Andrew P Mizisin; Peter W Stacpoole
Journal:  J Neuropathol Exp Neurol       Date:  2009-09       Impact factor: 3.685

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.